You are here » Home » Companies ยป Company Overview » Lupin Ltd

Lupin Ltd.

BSE: 500257 Sector: Health care
NSE: LUPIN ISIN Code: INE326A01037
BSE 00:00 | 24 Apr 2020 Lupin Ltd
NSE 05:30 | 01 Jan 1970 Lupin Ltd

Notice: Undefined property: stdClass::$market_capital_for_nse in /usr2/unibs/application/modules/live-market/views/scripts/company/bs-new-bse-nse-block.php on line 17
OPEN 825.00
PREVIOUS CLOSE 821.90
VOLUME 448909
52-Week high 890.25
52-Week low 505.00
P/E 23.31
Mkt Cap.(Rs cr) 39,744
Buy Price 877.25
Buy Qty 5055.00
Sell Price 884.00
Sell Qty 23.00
OPEN 825.00
CLOSE 821.90
VOLUME 448909
52-Week high 890.25
52-Week low 505.00
P/E 23.31
Mkt Cap.(Rs cr) 39,744
Buy Price 877.25
Buy Qty 5055.00
Sell Price 884.00
Sell Qty 23.00

Lupin Ltd. (LUPIN) - Chairman Speech


Notice: Undefined variable: pattern in /usr2/unibs/application/modules/live-market/views/scripts/company/annual-report.php on line 72

Company chairman speech

Dear Shareholders

I am pleased to present to you Lupin's FY2019 Annual Report.

It was a year of challenges but also a year of significant achievements for Lupin. Thefirst half of the year saw our revenues decline but by the third quarter our businessturned around and I am happy to share that we closed the year on a very strong note. Apartfrom the operating performance we also made meaningful progress on our strategic plan -on both complex generics and specialty.

Lupin's strong entrepreneurial spirit is powering growth internationally as we saw ourcore generics business in the US recovering in the second half of the year while ourIndia business continued its double-digit growth outperforming the market. Solosec ourbranded Women's Health product has also done well in the US and we continued to ramp upBipresso in Japan. In Europe we successfully launched NaMuscla an orphan drug fortreatment of myotonia. These remarkable products strengthen Lupin's branded portfoliogiving us a distinct position in delivering a truly diversified product portfolio.

During the year we achieved a unique milestone in our new drug research through analliance with AbbVie to develop and commercialise our novel drug a highly potent MALT1(Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor. This was arealisation of Dr. Gupta's dream to offer new drugs in areas of unmet needs. It is also aremarkable step forward in treating difficult to treat cancers offering new hope topatients and to drive strong value for our stakeholders.

At all levels across Lupin our integrated and inclusive culture continues to fosterdynamic and long-term growth for our people. We have been recognised by awards over theyears; and Lupin has retained its #1 position as a 'Great Place to Work' for 2019 in theBiotechnology & Pharmaceuticals sector. This is a remarkable achievement thanks toour unique culture that continues to be the bedrock of our organisation

We are an exceptional company with an extraordinary heritage. We have set our sightshigh. We are extremely motivated fully committed and truly brimming with confidence. Wehave set the course for lasting success and are building a promising future.

Thank you for your continued support and trust.

Regards

Mrs. Manju D. Gupta

Chairman


Notice: Undefined variable: mediaAbsUrl in /usr2/unibs/application/modules/live-market/controllers/CompanyController.php on line 6080